StreetInsider.com News Articles

Form 25-NSE/A LAVA Therapeutics NV Filed by: Nasdaq Stock Market LLC

Fri, 21 Nov 2025 12:03:00 -0500

si-local-file:///var/storage/secattach/20251121/25648461.html

Form 25-NSE/A LAVA Therapeutics NV Filed by: Nasdaq Stock Market LLC

Fri, 21 Nov 2025 12:03:00 -0500

si-local-file:///var/storage/secattach/20251121/25648461.html

Form S-8 POS LAVA Therapeutics NV

Fri, 21 Nov 2025 08:07:00 -0500

si-local-file:///var/storage/secattach/20251121/25647176.html

Form S-8 POS LAVA Therapeutics NV

Fri, 21 Nov 2025 08:07:00 -0500

si-local-file:///var/storage/secattach/20251121/25647176.html

Form S-8 POS LAVA Therapeutics NV

Fri, 21 Nov 2025 08:05:00 -0500

si-local-file:///var/storage/secattach/20251121/25647170.html

Form S-8 POS LAVA Therapeutics NV

Fri, 21 Nov 2025 08:05:00 -0500

si-local-file:///var/storage/secattach/20251121/25647170.html

Form SC 14D9/A LAVA Therapeutics NV Filed by: LAVA Therapeutics NV

Fri, 21 Nov 2025 08:03:00 -0500

si-local-file:///var/storage/secattach/20251121/25647152.html

Form SC 14D9/A LAVA Therapeutics NV Filed by: LAVA Therapeutics NV

Fri, 21 Nov 2025 08:03:00 -0500

si-local-file:///var/storage/secattach/20251121/25647152.html

Form 8-K LAVA Therapeutics NV For: Nov 21

Fri, 21 Nov 2025 08:01:00 -0500

si-local-file:///var/storage/secattach/20251121/25647131.html

Form 8-K LAVA Therapeutics NV For: Nov 21

Fri, 21 Nov 2025 08:01:00 -0500

si-local-file:///var/storage/secattach/20251121/25647131.html

Form SC TO-T/A LAVA Therapeutics NV Filed by: XOMA Royalty Corp

Fri, 21 Nov 2025 07:51:00 -0500

si-local-file:///var/storage/secattach/20251121/25647012.html

Form SC TO-T/A LAVA Therapeutics NV Filed by: XOMA Royalty Corp

Fri, 21 Nov 2025 07:51:00 -0500

si-local-file:///var/storage/secattach/20251121/25647012.html

XOMA completes acquisition of LAVA Therapeutics for $1.04 per share

Fri, 21 Nov 2025 07:45:10 -0500

XOMA Royalty Corporation (NASDAQ: XOMA) completed its acquisition of LAVA Therapeutics N.V. (NASDAQ: LVTX), the company announced November 21. LAVA shareholders received $1.04 in cash per share plus contingent value rights for potential future payments.

The transaction involved acquiring all outstanding common shares of LAVA with a nominal value of €0.12 per share. The contingent value rights provide holders with 75% of net proceeds from LAVA's two partnered assets and 75% of net proceeds from any out-license or sale of unpartnered programs, plus up to approximately $0.23 per right depending on final determination of certain liabilities.

As of the November 20 expiration

XOMA completes acquisition of LAVA Therapeutics for $1.04 per share

Fri, 21 Nov 2025 07:45:10 -0500

As of the November 20 expiration

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

Fri, 21 Nov 2025 07:45:00 -0500

EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) with a nominal value of €0.12 per share (“Shares”). LAVA shareholders received $1.04 in cash per Share and a non-transferrable contingent value right (“CVR”) per Share representing the right to receive certain cash payments, including (A) the right to receive, among other things, 75% of any net proceeds related to LAVA’s two partnered assets plus 75% of any net proceeds

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

Fri, 21 Nov 2025 07:45:00 -0500

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

Fri, 21 Nov 2025 07:45:00 -0500

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

Fri, 21 Nov 2025 07:45:00 -0500

Form 4 LAVA Therapeutics NV For: Nov 13 Filed by: HURLY STEPHEN A